One Canal Park, Suite 1120,
Cambridge, Massachusetts 02141
Stromedix, Inc., is a privately held biotechnology company based in Cambridge, Massachusetts, focused on innovative therapies for fibrosis and organ failure. Stromedix's investors include Atlas Venture, New Leaf Venture Partners, Bessemer Venture Partners, Red Abbey Venture Partners, and Frazier Healthcare.
Stromedix was acquired by Biogen on February 14, 2012.
Join Mergr to view all 119 acquisitions of life science companies in 2012, including 19 acquisitions by private equity firms, and 100 by strategics.
Out of 60 sectors in the Mergr database, life science ranked 18 in number of deals in 2012. The largest life science acquisition in 2012 was Amylin Pharmaceuticals - which was acquired by Bristol-Myers Squibb for $5.3B.
Join Mergr to view this profile - and discover more life science acquisitions of companies like Stromedix.
No obligation. Cancel anytime.